sk&f 86002 has been researched along with AIDS-Related Opportunistic Infections in 1 studies
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender Ignacio, RA | 1 |
| Lee, JY | 1 |
| Rudek, MA | 1 |
| Dittmer, DP | 1 |
| Ambinder, RF | 1 |
| Krown, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma[NCT00686842] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Drug supply unavailable.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who experienced an adverse event of grade 3 or greater (NCT00686842)
Timeframe: All study visits
| Intervention | participants (Number) |
|---|---|
| VEGF Inhibitor PTC299 | 7 |
1 trial available for sk&f 86002 and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; DNA, Viral; Enzyme | 2016 |